Table 2.

Correlations of CD11b, CD66b and CXCR2 expression with clinicopathological features.

Variables		CD11b					CD66b					CXCR2
		Low		High		p-Value	Low		High		p-Value	Low		High		p-Value
		N	%	N	%		N	%	N	%		N	%	N	%
Age (years)
	<55	53	38.7	73	52.9	0.018	72	52.2	55	39.9	0.040	61	42.4	68	47.6	0.377
	≥55	84	61.3	65	47.1		66	47.8	83	60.1		83	57.6	75	52.5
Tumor size
	T1	56	40.9	71	51.5	0.079	70	50.7	57	41.3	0.116	68	47.2	64	44.8	0.675
	T2/T3/T4	81	59.1	67	48.6		68	49.3	81	58.7		76	52.8	79	55.2
Nodal status
	N−	84	61.3	95	68.8	0.190	88	63.8	92	66.7	0.613	90	62.5	97	67.8	0.343
	N+	53	38.7	43	31.2		50	36.2	46	33.3		54	37.5	46	32.2
Histological grade
	1–2	48	35.8	14	10.2	<0.001	47	34.8	14	10.2	<0.001	49	34.8	16	11.3	<0.001
	3	86	64.2	123	89.8		88	65.2	123	89.8		92	65.3	126	88.7
Histology
	Ductal	109	79.6	118	87.4	0.082	109	79.6	120	88.2	0.051	111	78.2	124	87.3	0.041
	Other	28	20.4	17	12.6		28	20.4	16	11.8		31	21.8	18	12.7
Adjuvant chemotherapy
	No	40	29.4	26	18.8	0.041	25	18.3	42	30.4	0.019	38	26.6	32	22.4	0.409
	Yes	96	70.6	112	81.2		112	81.8	96	69.6		105	73.4	111	77.6
Basal-like phenotype
	No	55	40.4	41	29.9	0.069	46	33.8	52	37.7	0.505	56	39.4	45	31.5	0.160
	Yes (Basal)	81	59.6	96	70.1		90	66.2	86	62.3		86	60.6	98	68.5
Molecular apocrine phenotype
	No	61	48.4	91	68.4	0.001	71	55.9	83	61.5	0.359	66	50.0	93	66.4	0.006
	Yes (Molecular apocrine)	65	51.6	42	31.6		56	44.1	52	38.5		66	50.0	47	33.6

Footnote: Basal-like phenotype was considered in the case of positive staining for cytokeratin 5/6 and/or EGFR (>10% of tumor cells stained in IHC); Molecular apocrine phenotype was defined in TNBC tumors that express both AR (androgen receptor) and FOXA1 (Forkhead box protein A1) biomarkers.